La cadena de opciones muestra datos clave de las opciones de acciones de NKGen Biotech a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para NKGen Biotech..

NKGen Biotech (NASDAQ:NKGN) Bolsa, Cadena de Opciones

NKGen Biotech

NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.

NKGen Biotech Inc

GreenPower Motor Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GP#NASDAQ">GP</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.16) by 12.5 percent. The company reported quarterly sales of $5.347 million which missed the analyst consensus estimate of $7.967 million by 32.88 percent. This is a 36.35 percent decrease over sales of $8.400 million the same period last year.

Earnings

Earnings Misses

News

GreenPower Motor Co Q2 2025 GAAP EPS $(0.18) Misses $(0.16) Estimate, Sales $5.347M Miss $7.967M Estimate

Beam Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEEM#NASDAQ">BEEM</a>) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $(0.12) by 175 percent. The company reported quarterly sales of $11.482 million which missed the analyst consensus estimate of $18.863 million by 39.13 percent. This is a 30.35 percent decrease over sales of $16.486 million the same period last year.

Earnings Beats

BEEM

Beam Global Q3 2024 GAAP EPS $0.09 Beats $(0.12) Estimate, Sales $11.482M Miss $18.863M Estimate

Lantmännen will invest more than 100 million euros in a state-of–the-art <a href="https://www.globenewswire.com/Tracker?data=D-7Y-KVbP6QZknfadXEZ-FyiOL801tmcb6MoPLIt1GBtRzzMxYqB5y0WMAfkDOuP8wF9RdBMPWvDS7IIKC_OkWudCUCt9vi-8ARGYU9fdadf5aFadydlfMoC2c0oEek0wq9shl6f0tFxH4iEsBbG2plhHfhgHB7WME97-NbSZIM6dfFRmaj3AkU_gZXrXeRD6wSfFlbL5NZEKQdFWd05Ix8BUt1dMN_MHpAiD0GLnSSve8knOhEkT3alPDLqD0Z4qqemEbKkxRZ3MJ3oKFuKXBYY26VDZ92n-tTgubAPhQo=">factory in Sweden</a>, while partnering with Ingredion to develop a differentiated portfolio of plant-based protein isolates based on yellow peas. Construction of the production plant will be completed in 2027.

INGR

Reported Earlier, Ingredion And Lantmännen Forge Strategic Alliance To Boost European Plant-Based Protein Market, Invest Over €100M In New Pea Protein Facility

Macro Economic Events

Econ #s

Economics

U.K. Trade Balance Non-EU For September -5.31B Vs. -4.85B (Revised) Prior

U.K. Trade Balance For September -16.32B Vs. -15.70B Est.; -15.21B (Revised) Prior

U.K. Monthly Gross Domestic Product (GDP) 3M/3M Change For September 0.1% Vs. 0.2% Est.; 0.2% Prior

U.K. Manufacturing Production (MoM) For September -1.0% Vs. 0.0% Est.; 1.3% (Revised) Prior

U.K. Industrial Production (MoM) For September -0.5% Vs. 0.1% Est.; 0.5% Prior

U.K. Gross Domestic Product (QoQ) Preliminary For Q3 0.1% Vs. 0.2% Est.; 0.5% Prior

U.K. Gross Domestic Product (YoY) Preliminary For Q3 1.0% Vs. 0.1% Est.; 0.7% Prior

U.K. Gross Domestic Product (MoM) For September -0.1% Vs. 0.2% Est.; 0.2% Prior

U.K. Business Investment (QoQ) Preliminary For Q3 1.2% Vs. 0.6% Est.; 1.4% Prior

Billionaire investor David Tepper&#8216;s Appaloosa Management reduced its stake in Alibaba Group Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) by 5% in the third quarter, despite his recent public enthusiasm for Chinese investments, according to regulatory filings released Thursday.
What Happened: The reduction comes just months after Tepper declared that he <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/41050711/stocks-rise-as-china-signals-more-stimulus-billionaire-david-tepper-bets-big-on-everythi">would buy &#8220;everything&#8221; China-related</a> amid Beijing&#8217;s stimulus efforts. Despite the trim, Alibaba remains Appaloosa&#8217;s largest holding, representing 15.75% of its $6.7 billion equity portfolio.
The hedge fund&#8217;s third-quarter moves reveal a complex strategy toward Chinese investments. While reducing positions in the iShares China Large-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXI#NYSE">FXI</a>), KraneShares CSI China Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWEB#NYSE">KWEB</a>), and Baidu Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>), Tepper more than doubled his stake in PDD Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) and increased positions in JD.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) and KE Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>).
The filing also revealed significant reductions in major U.S. technology holdings. Appaloosa sold 275,000 shares of Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), representing an 8.59% reduction while cutting its Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) position by 211,356 shares, or 21.89%. The fund also reduced its stake in Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) by 310,000 shares, a 49.6% decrease, and trimmed its position in Alphabet Inc Class C (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>).
See Also: <a href="https://www.benzinga.com/news/global/24/11/41998381/tesla-earnings-will-be-hit-hardest-if-7500-ev-credit-is-cut-warns-gary-black-citing-80-dependence-on-ev-sales-please-do-the-math">Tesla Earnings Will Be Hit Hardest If $7.5K EV Credit Gets Cut By Trump, Warns Gary Black: &#8216;Do The Math&#8217;</a>
Why It Matters: Overall, Tepper&#8217;s exposure to Chinese stocks and ETFs increased to 38% of his equity portfolio in the third quarter, up from 26% in the previous quarter. This positions him, alongside Scion Asset Management&#8216;s Michael Burry, as one of the few prominent hedge fund managers <a href="https://www.benzinga.com/markets/equities/24/10/41248334/big-short-investor-michael-burrys-china-bet-pays-off-as-top-picks-surge-nearly-60-in-2-months">maintaining significant Chinese market exposure</a>. 
These portfolio adjustments come as Chinese stocks face headwinds from disappointing fiscal policies and persistent economic challenges, including weak consumer spending and an unstable property market. Market observers note that geopolitical tensions and potential tariff increases add further <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41902202/trumps-china-hawks-rumored-for-top-roles-yuan-hits-3-month-low">uncertainty to the investment landscape</a>.
The details of these transactions were disclosed in a Form 13F filing, a quarterly report required by the Securities and Exchange Commission for institutional investment managers overseeing more than $100 million in qualifying securities.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/41998258/cathie-wood-keeps-betting-on-amazons-haul-play-ark-loads-up-6m-worth-of-shares">Cathie Wood Keeps Betting On Amazon&#8217;s &#8216;Haul&#8217; Play: Ark Loads Up $6M Worth Of Shares</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" target="_blank" rel="noreferrer noopener"></a>

Asia

Equities

Markets

ETFs

AMZN

BABA

BEKE

BIDU

GOOG

KWEB

MSFT

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Billionaire David Tepper's China Puzzle: Appaloosa Cuts Alibaba Stake While Doubling Down On PDD

QUBT

Reported Earlier, Quantum Computing Secures $40M Through Registered Direct Offering, Pricing 16M Shares At $2.50 Each in At-the-Market Deal

Michael Saylor, CEO of MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), deemed the Donald Trump-led Republican triumph the &#8220;biggest&#8221; bullish catalyst for Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) over the last four years.
What Happened: In an interview with CNBC on Thursday, Saylor said that the &#8220;red wave&#8221; has been &#8220;incredibly auspicious&#8221; for Bitcoin and the broader cryptocurrency industry.
The Bitcoin bull anticipated a friendlier SEC at the helm amid speculations of current chair Gary Gensler stepping aside.
&#8220;It&#8217;s very good for the cryptocurrency industry. We&#8217;re going to see a lot more pro-Bitcoin policies. We are going to see a digital assets framework. We are going to see an end to the war on crypto.,&#8221; Saylor predicted.
Don&#8217;t Miss:
<ul>
<li>Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O&#8217;Reilly and Rudy Giuliani are using this platform to <a href="https://www.benzinga.com/money/american-hartford-gold">create customized gold IRAs to help shield their savings from inflation and economic turbulence.</a></li>
<li>1 in 4 Americans own a share of Bitcoin according to NASDAQ — <a href="https://www.benzinga.com/money/binance-100">this platform touts returns as high as 12.5% APY and is giving $100 in welcome rewards if you sign up today.</a></li>
</ul>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&quot;The red wave is probably the biggest thing that has happened in the past four years for bitcoin&quot; &#8211; <a href="https://twitter.com/MicroStrategy?ref_src=twsrc%5Etfw">@MicroStrategy</a> founder &amp; chairman <a href="https://twitter.com/saylor?ref_src=twsrc%5Etfw">@saylor</a> on his crypto expectations under a second Trump presidency. <a href="https://t.co/9BYAYgLGe8">pic.twitter.com/9BYAYgLGe8</a>
&mdash; CNBCOvertime (@CNBCOvertime) <a href="https://twitter.com/CNBCOvertime/status/1857179737606459844?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
With the election uncertainty behind, Saylor also ruled out any major bearish events for Bitcoin in the foreseeable future.
&#8220;I am planning the $100,000 party, and I am thinking it is probably going to be New Year&#8217;s Eve at my house. So, I would be surprised if we don&#8217;t go through $100,000 in November or December,&#8221; Saylor said in a burst of enthusiasm.
See Also: Dogecoin millionaires are increasing –<a href="https://www.benzinga.com/money/dogecoin-millionaires"> investors with $1M+ in DOGE revealed!</a>
Why It Matters: Saylor&#8217;s bullish sentiment aligned with the ongoing success of his company&#8217;s publicly-traded stock. 
MicroStrategy&#8217;s shares hit a record high earlier this week, pushing the firm&#8217;s market valuation to $72.26 billion, a $50 billion increase since September 6. This gain <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41961419/bitcoin-proxy-microstrategy-added-more-to-its-market-cap-in-last-2-months-than-what-ford-is-worth-currently">surpassed the total capitalization</a> of Ford Motor Co. (F) and Cognizant Technology Solutions Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>).
The firm, known famously as Bitcoin&#8217;s biggest corporate holder, was sitting on unrealized profits of over $12.7 billion as of this writing, <a href="https://bitcointreasuries.net/" target="_blank" rel="noreferrer noopener">according&nbsp;</a>to data from bitcointreasuries.net.&nbsp;&nbsp;
The company&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41646462/michael-saylor-says-bitcoin-remedy-to-fix-unhealthy-balance-sheets-as-microstrategy-unveil" target="_blank" rel="noreferrer noopener">announced plans</a>&nbsp;to raise as much as $42 billion in equity and debt funding over the next three years to accumulate more Bitcoin.
Price Action: At the time of writing, Bitcoin was exchanging hands at $88,121.00, down 1.89% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA.." target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>. Shares of MicroStrategy closed 0.22% lower at $327.67 during Thursday&#8217;s regular trading session.
Photo Courtesy: Wikimedia
Read Next: 
<ul>
<li>This well known prop trading firm is offering 100% of your first $25,000 profit per account and 90% after that. <a href="https://www.benzinga.com/money/apex-trader-funding">Here's how to get a special 50% OFF CODE that lets you start out with monthly investments as low as $147 today.</a></li>
<li>If you invested $100 in DOGE when Elon Musk first tweeted about it in 2019,<a href="https://www.benzinga.com/money/etoro-doge"> here&#8217;s how much you&#8217;d have today</a>.</li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

CTSH

MSTR

Michael Saylor Is Planning A Bitcoin $100K Party At His House, Expects End Of War On Crypto Under Trump

AGAE

Reported Earlier, AGAE Responds To Knighted's Legal Claims, Alleging Roy Choi's Attempt To Undermine Board's Strategic Decisions For Short-Term Gains

Elon Musk&#8216;s SpaceX has been increasing its launch cadence, enabling 17 launches in the last 31 days, and exceeding its <a href="https://www.benzinga.com/news/24/01/36860379/one-month-into-2024-spacex-is-already-falling-short-of-its-own-launch-targets-temporary-setback-or-c">monthly launch targets</a>.
What Happened: SpaceX&#8217;s Falcon 9 rocket launched 24 Starlink satellites to low-Earth orbit from Florida on Thursday, marking its 17th launch in 31 days.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Falcon 9 lifts off from pad 40 in Florida, completing our 17th launch in 31 days! <a href="https://t.co/w0snRDcUA9">pic.twitter.com/w0snRDcUA9</a>
&mdash; SpaceX (@SpaceX) <a href="https://twitter.com/SpaceX/status/1857082099154456924?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
SpaceX launched almost every other day in the last 31 days, exceeding its target set at the start of the year of 12 launches every month. 
However, the Musk-led space giant <a href="https://www.benzinga.com/news/24/07/39612042/elon-musks-spacex-launches-67-missions-in-first-half-of-2024-trailing-own-targets">fell short of its launch targets</a> in the first half of 2024, completing just 67 missions, not including its Starship test flights. The company is now trying to reach its launch target for the whole year by amping up launches in the remaining months.
Why It Matters: SpaceX has already exceeded 100 launches this year, outrunning its 96 launches in 2023. 
SpaceX VP of Launch Kiko Dontchev said earlier this month that the company will <a href="https://www.benzinga.com/news/24/11/41767169/spacex-completes-400th-successful-falcon-launch-to-date-but-will-miss-target-of-144-launches-in-2024">not make its goal of 144 launches this year</a> but is still targeting 30 more launches, or one launch every two days, for the rest of the year.
SpaceX is currently using its Falcon launch vehicles for the payload carrying missions. The company is also testing its Starship launch vehicle, whose next test flight is expected <a href="https://www.benzinga.com/general/space/24/11/41871398/spacex-aims-to-launch-starship-once-every-2-weeks-by-late-2025-ceo-elon-musk-says-we-will-be-much-faster">as early as Nov. 18</a>. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/partner/fintech/24/11/41939694/the-power-of-leverage-global-broker-octa-lays-out-the-ins-and-outs-of-this-trading-tool-for-trade">Ford Cuts Capri, Explorer EV Output Due To &#8216;Significantly Lower Than Expected Demand&#8217; After Pausing F-150 Lightning Production</a></li>
</ul>
Photo courtesy: SpaceX

SPACE

Tech

SpaceX Speeds Up Mission Launches With A New One Taking Off Every Other Day Over Last Month As It Races Towards Its 2024 Target

The Share Repurchase is being made pursuant to the Company's existing $50.0 million share repurchase program. On November 14, 2024, the Company announced that its Board of Directors authorized a share repurchase program, beginning on the date thereof and continuing through and including December 31, 2025. After the completion of the Share Repurchase described above, there will be $35.0 million remaining under the Company's share repurchase program.

Kodiak Gas Prices Upsized Offering Of 5.7M Common Shares At $34.50/Share; Proceeds To Selling Stockholder, $15M Buyback To Follow

The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index remained in the &#8220;Greed&#8221; zone on Thursday.
U.S. stocks settled lower on Thursday, with the Dow Jones falling more than 200 points during the session as investors digested recent economic reports.
U.S. initial jobless claims declined by 4,000 from the previous week to 217,000 in the week ending Nov. 9, compared to market estimates of 223,000. U.S. producer prices rose 0.2% month-over-month in October compared to a revised 0.1% gain in September, in line with market expectations.
Shares of Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) fell around 5.8% on Thursday after recording sharp gains in the recent period. The small-cap benchmark Russell 2000 tumbled over 1% during the session.
Cisco Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) shares fell over 2% on Thursday despite reporting better-than-expected results for its first quarter.
Most sectors on the S&amp;P 500 closed on a negative note, with consumer discretionary, industrials, and healthcare stocks recording the biggest losses on Thursday. However, information technology and energy stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 207 points to 43,750.86 on Thursday. The S&amp;P 500 fell 0.60% to 5,949.17, while the Nasdaq Composite fell 0.64% to close at 19,107.65 during Thursday's session.
Investors are awaiting earnings results from Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), Spectrum Brands Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>), and RLX Technology Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLX#NYSE">RLX</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 60.3, the index remained in the &#8220;Greed&#8221; zone on Thursday, versus a prior reading of 65.8.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41971544/jim-cramer-recommends-microsoft-praises-american-water-works-for-being-consistent">Jim Cramer Recommends Microsoft, Praises American Water Works For Being &#8216;Consistent&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Pre-Market Outlook

Trading Ideas

CSCO

TSLA

Dow Dips Over 200 Points Following Economic Reports, Tesla Tumbles On Potential Removal Of EV Tax Credit: Fear Index Remains In 'Greed' Zone

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
<ul>
<li>Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity</li>
<li>More than 300,000 people in the US suffer from chronic spontaneous urticaria (CSU) that is inadequately controlled by antihistamines</li>
<li>FDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decade &nbsp;</li>
</ul>

REGN

Dupixent's sBLA Resubmission Accepted By FDA; Phase 3 Data Demonstrate Significant Itch And Hive Reduction For Chronic Urticaria Patients

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
NKGen Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/nkgn-stock-quote/">NKGN</a>) stock is rocketing higher on Thursday as the clinical-stage biotechnology company prepares to <a href="https://finance.yahoo.com/news/nkgen-biotech-present-positive-snk01-120500650.html">present new biomarker data on SNK01</a>.



This is the company&rsquo;s treatment candidate for Alzheimer&rsquo;s disease. It&rsquo;s going to provide this data to those attending the Alzheimer&rsquo;s Association International Conference. This is set to take place from July 28 through Aug. 1.



The focus of the presentation will be on SNK01&rsquo;s ability to reduce &alpha;-synuclein in Alzheimer&rsquo;s patients. That&rsquo;s important as &alpha;-synuclein has been tied to worse cognitive function for Alzheimer&rsquo;s patients.



NKGen Biotech will hold its press conference on July 30. It will start at 7:30 a.m. Eastern Time. The event will end at 4:15 p.m. Eastern Time that same day. Hosting the event is company chairman and CEO Paul Song.



<h2>How This Affects NKGN Stock</h2>



NKGN stock is already up 17.7% as of Thursday morning alongside excitement for the upcoming presentation. This brings with it heavy trading with more than 33 million shares changing hands. That&rsquo;s already well above its daily average trading volume of about 1.5 million shares.



It&rsquo;s also possible that NKGN stock will see another rally alongside its presentation. That means investors will want to check back in on it when July 30 rolls around.



Here are more of the most recent stock market stories that traders need to know about on Thursday!



We are offering coverage of all of the latest stock market news for today! That includes what&rsquo;s happening with shares of Agenus&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/agen-stock-quote/">AGEN</a>) stock, Lilium&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/lilm-stock-quote/">LILM</a>) stock and Wayfair&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/w-stock-quote/">W</a>) today. All of this news is ready at the links below!



<h2>More Thursday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-agenus-agen-stock-down-55-today/">Why Is Agenus (AGEN) Stock Down 55% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/lilm-stock-pops-as-lilium-bags-evtol-jet-order/">LILM Stock Pops as Lilium Bags eVTOL Jet Order</a></li>



<li><a href="https://investorplace.com/2024/07/dear-wayfair-stock-fans-mark-your-calendars-for-july-26/">Dear Wayfair Stock Fans, Mark Your Calendars for July 26</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/why-is-nkgen-biotech-nkgn-stock-up-18-today-july-18th/">Why Is NKGen Biotech (NKGN) Stock Up 18% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is NKGen Biotech (NKGN) Stock Up 18% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Warner Bros. (NASDAQ:<a href="https://investorplace.com/stock-quotes/wbd-stock-quote/">WBD</a>) stock is in the news Thursday as investors react to reports that the entertainment company is <a href="https://finance.yahoo.com/video/warner-bros-discovery-considering-break-140403992.html">considering a spinoff</a> of its streaming division.



According to these reports, Warner Bros. is weighing options that would have it breaking up its business. That includes splitting off its streaming and studio businesses from its television division.



Reports of this plan come as Warner Bros. continues to deal with growing debt. The company is still sitting with $39 billion of debt and that&rsquo;s one of the factors that&rsquo;s weighing down its shares recently.



<h2>WBD Stock Reaction Today</h2>



Investors in Warner Bros. appear excited about the prospect of the company splitting off its streaming division. These reports sent shares of WBD 6.6% higher on Thursday morning.



Alongside that rally comes increased trading of WBD stock. This has nearly 32 million shares of the stock changing hands as of this writing. To put that in perspective, the company&rsquo;s daily average trading volume is about 29.1 million shares.



While WBD stock is up on Thursday, it&rsquo;s been a rough year for the company&rsquo;s shares. Year-to-date the stock is still down 24%. It&rsquo;s also 30.6% lower over the last 12 months.



Investors who are seeking out even more of the most recent stock market stories are going to want to keep reading!



We are offering up insight into all of the biggest stock market news that traders need to know about on Thursday! Among that is what has shares of NKGen Biotech&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/nkgn-stock-quote/">NKGN</a>), Trump Media &amp; Technology Group&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/djt-stock-quote/">DJT</a>) and Agenus&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/agen-stock-quote/">AGEN</a>) stock moving today. You can find out more on these matters down below!



<h2>More Thursday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-nkgen-biotech-nkgn-stock-up-18-today-july-18th/">Why Is NKGen Biotech (NKGN) Stock Up 18% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/trump-media-stock-alert-sec-sues-former-digital-world-ceo-patrick-orlando/">Trump Media Stock Alert: SEC Sues Former Digital World CEO Patrick Orlando</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-agenus-agen-stock-down-55-today/">Why Is Agenus (AGEN) Stock Down 55% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/wbd-stock-pops-as-warner-bros-considers-streaming-spinoff/">WBD Stock Pops as Warner Bros. Considers Streaming Spinoff</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

WBD Stock Pops as Warner Bros. Considers Streaming Spinoff

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Intuitive Surgical (NASDAQ:<a href="https://investorplace.com/stock-quotes/isrg-stock-quote/">ISRG</a>) stock is on the move Thursday after the company&rsquo;s shares were given a <a href="https://www.streetinsider.com/Analyst+PT+Change/Intuitive+Surgical+%28ISRG%29+PT+Raised+to+%24490+at+Barclays/23476587.html">price target increase</a> by Barclays analysts.



Barclays analyst Matt Miksic increased the firm&rsquo;s price target for ISRG stock from $430 per share to $490 per share. That&rsquo;s a potential upside of 17.5% over its prior closing price. It&rsquo;s also above the <a href="https://www.marketbeat.com/stocks/NASDAQ/ISRG/forecast/">analysts&rsquo; consensus price prediction</a> of $426.53 per share.



The Barclays analyst reiterated the firm&rsquo;s &ldquo;overweight&rdquo; rating for ISRG stock alongside that price target increase. For comparison, the analysts&rsquo; consensus rating for Intuitive Surgical shares is moderate buy based on 19 opinions.



<h2>More Analyst Coverage of ISRG Stock</h2>



&nbsp;J.P. Morgan analysts also recently weighed in on Intuitive Surgical. Here&rsquo;s <a href="https://www.medtechdive.com/news/jj-abbott-intuitive-medtech-earnings-q2/721427/">what they said</a> in a statement collected by MedTechDive. 




&ldquo;We think, if anything, the environment has improved modestly in China barring competitive headwinds, and while bariatric surgery should continue to remain pressured, given the low to mid-single digit % of procedures, we aren&rsquo;t overly concerned.&rdquo;




ISRG stock is down 2.5% as of Thursday afternoon. This comes with some 1.7 million shares traded, as compared to its daily average of about 1.3 million shares.



Investors will want to stick around for more of the most recent stock market stories today!



We have all of the hottest stock market news investors will want to read about on Thursday! A few examples include what&rsquo;s happening with shares of Oklo&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/oklo-stock-quote/">OKLO</a>), Warner Bros.&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/wbd-stock-quote/">WBD</a>) and NKGen Biotech&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/nkgn-stock-quote/">NKGN</a>) stock today. All of this info is ready at the links below!



<h2>More Stock Market News for Thursday</h2>



<ul><li><a href="https://investorplace.com/2024/07/cathie-wood-is-betting-big-on-nuclear-energy-via-oklo-stock-what-to-watch/">Cathie Wood Is Betting Big on Nuclear Energy Via Oklo Stock. What to Watch.</a></li>



<li><a href="https://investorplace.com/2024/07/wbd-stock-pops-as-warner-bros-considers-streaming-spinoff/">WBD Stock Pops as Warner Bros. Considers Streaming Spinoff</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-nkgen-biotech-nkgn-stock-up-18-today-july-18th/">Why Is NKGen Biotech (NKGN) Stock Up 18% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/barclays-just-raised-its-price-target-on-intuitive-surgical-isrg-stock/">Barclays Just Raised Its Price Target on Intuitive Surgical (ISRG) Stock</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Barclays Just Raised Its Price Target on Intuitive Surgical (ISRG) Stock

NKGen Biotech (NKGN) has issued an announcement. Pierre Gagnon has stepped down from his role as Chief Operating Officer of NKGen Biotech, Inc., ef...

NKGen Biotech COO Pierre Gagnon Steps Down, Remains Advisor

NKGen Biotech receives non-compliance notification from Nasdaq

An announcement from NKGen Biotech (NKGN) is now available. NKGen Biotech, Inc. is facing a delay in submitting its quarterly financial report due ...

NKGen Biotech Faces Nasdaq Compliance Challenges

NKGen Biotech ( ($NKGN) ) has shared an update. NKGen Biotech, Inc. is set to join the H.C. Wainwright 26th Annual Global Investment Conference on ...

NKGen Biotech to Showcase at Global Investment Conference

NKGen Biotech ( ($NKGN) ) has provided an update. NKGen Biotech, Inc. has amended its forward purchase agreement to increase both the prepayment sh...

NKGen Biotech Expands Agreement Terms and Restructures COO Role

NKGen Biotech ( ($NKGN) ) just unveiled an update. NKGen Biotech, Inc. is experiencing a significant change in its leadership structure as director...

NKGen Biotech Announces Leadership Shuffle on Anniversary

NKGen Biotech ( ($NKGN) ) just unveiled an update. NKGen Biotech Inc. has announced the appointment of Michael Klowden and Kathleen Scott as new di...

NKGen Biotech Welcomes New Directors and Assigns Committees

AGEN

ISRG

LILM

NKGN

OKLO

Health Care

Press Releases

NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer's Association International Conference

NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer's Association International Conference

NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report

NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

NKGen Biotech's Positive Phase 1 Clinical Data in Moderate Alzheimer's Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial

Comments

NKGen Biotech

NKGen Biotech (NKGN) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL